TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39568724
Drug: 15 g oat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g oat polar lipids (OPL)
Study: 39568724
Drug: 18 g rapeseed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g rapeseed oil (RSO)
Study: 39568790
Drug: Self-administered intravaginal
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intravaginal 5% 5-Fluorouracil (5FU) cream
Study: 39569450
Drug: Stool energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stool energy content at discharge (AN-DIS: 5.72 ± 0.86 kcal/g)
Study: 39569542
Drug: Patient-administered audio
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-administered audio recordings
Study: 39570031
Drug: S315 (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: S315 (480 mg, 960 mg, 1920 mg, 3840 mg, 7680 mg)
Study: 39570031
Drug: S315 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: S315 (various doses)
Study: 39570078
Drug: Anticoagulant
Normalized name: Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulant
Study: 39570620
Drug: Olverembatinib 30
Normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olverembatinib 30 mg every other day
Study: 39570620
Drug: Olverembatinib 40
Normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olverembatinib 40 mg every other day
Study: 39570620
Drug: Olverembatinib 50
Normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olverembatinib 50 mg every other day
Study: 39570620
Drug: Prior ponatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior ponatinib treatment
Study: 39570708
Drug: 177Lu-Dotatate treatment
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-Dotatate treatment
Study: 39570708
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy (everolimus [Afinitor] and sunitinib [Sutent])
Study: 39570992
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (oCEE) - Premarin, 0.45 mg/d
Study: 39570992
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (tE2) - Climara, 50 μg/d
Study: 39571342
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (200 mL daily, ∼600 mg nitrate)
Study: 39571342
Drug: Placebo (∼60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (∼60 mg nitrate)
Study: 39571596
Drug: Short-course hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course hypofractionated proton beam therapy
Study: 39571744
Drug: AbobotulinumtoxinA (AboBoNT-A)
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA (AboBoNT-A) injections
Study: 39571744
Drug: AbobotulinumtoxinA (AboBoNT-A)
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA (AboBoNT-A) injections with guidance technique
Study: 39572389
Drug: Combined CRMRF
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CRMRF and PNF treatment
Study: 39572395
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg once daily) in combination with bendamustine and rituximab (IBR) for six 28-day cycles
Study: 39572739
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) group, 250 µg injected into the silicone oil after surgery and at weeks 3 and 6 postoperatively.
Study: 39572979
Drug: Nivolumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 300 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks until disease progression or unacceptable toxicity
Study: 39572979
Drug: Nivolumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 300 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks
Study: 39574186
Drug: Prochlorperazine maleate
Normalized name: Prochlorperazine Maleate
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prochlorperazine maleate (oral, three times daily for 24 hours)
Study: 39574186
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, three times daily for 24 hours)
Study: 39574220
Drug: MBX 2109
Normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBX 2109 (200, 400, 600, and 900 μg)
Study: 39574348
Drug: Brensocatib (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib (single oral dose)
Study: 39574508
Drug: IVIG 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 10% administered at various dosing regimens (0.4-2 g/kg once every 1-4 weeks)
Study: 39574508
Drug: IVIG 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 10% with dose splitting over multiple days
Study: 39574508
Drug: IVIG 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 10% with dosing intervals more frequent than Q4W
Study: 39575028
Drug: Neoadjuvant anti-PD-L1
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant anti-PD-L1 (Durvalumab) and anti-CTLA-4 (Tremelimumab) for three cycles of four weeks/cycle along with external beam radiation for five weeks, followed by wide surgical resection and adjuvant Durvalumab monotherapy for four cycles.
Study: 39575188
Drug: Fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 160 mg once daily along with 1 g of mesalamine three times daily
Study: 39575188
Drug: Placebo along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo along with 1 g of mesalamine three times daily
Study: 39575565
Drug: EMB-09 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMB-09 (a novel Fc-silenced tetravalent PD-L1/OX40 bispecific antibody)
Study: 39575728
Drug: Unconditional Cash
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconditional Cash Transfers (UCT) + Medium-Quantity Lipid-Based Nutrient Supplement (LNS)
Study: 39575728
Drug: Unconditional Cash
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconditional Cash Transfers (UCT) + Medium-Quantity Lipid-Based Nutrient Supplement (LNS) + Social and Behaviour Change Communication (SBCC)
Study: 39575944
Drug: nPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nPAP therapy (BiPAP, APAP, CPAP, ASV)
Study: 39575944
Drug: nPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nPAP therapy
Study: 39576286
Drug: CT (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (conventional therapy)
Study: 39576637
Drug: Intervention clinics
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention clinics with nurse care management for OUD treatment
Study: 39576962
Drug: Itacitinib 200
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib 200 mg daily from day -3 through +100 or +180, followed by a taper
Study: 39576962
Drug: Itacitinib 200
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib 200 mg daily
Study: 39577214
Drug: IV calcium
Normalized name: Viactiv Calcium Plus D
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV calcium chloride 90 mg (C90D)
Study: 39577214
Drug: IV calcium
Normalized name: Viactiv Calcium Plus D
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV calcium chloride 180 mg (C180D)
Study: 39577214
Drug: IV calcium
Normalized name: Viactiv Calcium Plus D
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV calcium pretreatment (both doses)
Study: 39577511
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dd-cfDNA and NTproBNP
Study: 39577511
Drug: Cut-off point
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cut-off point of 0.10% for dd-cfDNA and 1,000 UI/ml for NTproBNP
Study: 39577708
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (300,000 IU bolus followed by 1400 IU daily for 150 days)
Study: 39577828
Drug: Pred Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pred Low (5 mg/d, every other week × 6 months)
Study: 39577828
Drug: Pred High
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pred High (20 mg prednisone taper, every other month × 3 months)
Study: 39577828
Drug: Pred PRN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pred PRN (20 mg prednisone taper × 3 courses maximum if sperm counts were declining or 0)
Study: 39577920
Drug: Early-start group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-start group (100 mg acetylsalicylic acid starting on the third day after surgery until the 90th day)
Study: 39577920
Drug: Late-start group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-start group (100 mg acetylsalicylic acid starting on the 30th day after surgery until the 90th day)
Study: 39577921
Drug: Intravenous glibenclamide
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glibenclamide (8·6 mg over 72 h)
Study: 39577975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sputum-Xpert Ultra with AlereLAM
Study: 39577975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sputum-Xpert Ultra with Urine-Xpert Ultra
Study: 39577975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three tests (Sputum-Xpert Ultra, AlereLAM, Urine-Xpert Ultra)
Study: 39578038
Drug: DOR/DTG/3TC (co-formulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOR/DTG/3TC (co-formulated doravirine, dolutegravir, and lamivudine) once daily
Study: 39578265
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannula (HFNC) at 50 to 60 L.min
Study: 39578347
Drug: GN-037 cream
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GN-037 cream
Study: 39578347
Drug: Clobetasol 17-propionate
Normalized name: clobetasol 17-propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol 17-propionate (CP) cream
Study: 39578347
Drug: Vehicle (V)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (V) cream
Study: 39578921
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical sirolimus applied to the face for 24 weeks
Study: 39578921
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical sirolimus
Study: 39580145
Drug: Faricimab 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab 6.0 mg every 8 weeks (Q8W)
Study: 39580145
Drug: Faricimab 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab 6.0 mg according to a personalized treat-and-extend (T&E)-based regimen
Study: 39580145
Drug: Aflibercept 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2.0 mg every 8 weeks (Q8W)
Study: 39580437
Drug: Empirical antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antibiotic therapy
Study: 39580437
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to guidelines for empirical antibiotic therapy
Study: 39580437
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to guidelines for therapy duration
Study: 39580437
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) level exceeding 100 mg/L
Study: 39580437
Drug: Planned post-discharge
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned post-discharge treatment
Study: 39580437
Drug: Temporal trends
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporal trends in adherence to treatment duration guidelines
Study: 39580793
Drug: Hydroxyurea and
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea and chronic transfusion therapy (HAT)
Study: 39581197
Drug: Tislelizumab 200
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg plus platinum-based doublet chemotherapy followed by adjuvant tislelizumab 400 mg every 6 weeks.
Study: 39581197
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus platinum-based doublet chemotherapy followed by placebo every 6 weeks.
Study: 39581202
Drug: Mirikizumab 900
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 900 mg IV at weeks 0, 4, and 8, then 300 mg SC every 4 weeks from weeks 12 to 52
Study: 39581380
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg orally once daily in continuous 21-day cycles
Study: 39581631
Drug: Cenerimod 2
Normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenerimod 2 mg
Study: 39581729
Drug: 1L therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1L therapy (first systemic treatment for A/R EC with or without radiotherapy)
Study: 39581739
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health (mHealth) and graphic medicine (comic) programme for mental health alongside HIVST
Study: 39581739
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HIVST, a livelihoods programme, and mHealth mental health programme
Study: 39581887
Drug: 4 implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 implants (4-I)
Study: 39581887
Drug: 6 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 implants (6-I)
Study: 39581957
Drug: Intravenous omadacycline
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omadacycline 100 mg over 0.5 h
Study: 39581957
Drug: Oral omadacycline
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral omadacycline 300 mg
Study: 39582029
Drug: 750,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750,000 IU of vitamin D3 via enteral or oral route
Study: 39582048
Drug: Suspended/stopped anti-cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspended/stopped anti-cancer treatment
Study: 39583219
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy candidates identified based on IPC criteria
Study: 39583219
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy candidates with BSA >10%
Study: 39583219
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy candidates with history of psoriasis affecting special areas
Study: 39583219
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy candidates with prior use of topical therapy
Study: 39583219
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy candidates with PASI scores ≤12
Study: 39583952
Drug: Ipilimumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (1 mg/kg IV every 6 weeks) plus Nivolumab (240 mg IV every 2 weeks)
Study: 39583953
Drug: Novel hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel hormonal therapies
Study: 39584139
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg enterally once daily for 7 days
Study: 39584139
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg intravenously every 6-8 hours for 7 days
Study: 39584380
Drug: C10 monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: C10 monoclonal antibody (mAb) targeting SARS-CoV-2
Study: 39584380
Drug: C10-based Chimeric
Approvals — FDA: no, EMA: no, PMDA: no
Description: C10-based Chimeric Antigen Receptor (CAR)-T cells
Study: 39584557
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT)
Study: 39584789
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) 45 mg/m2, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO)
Study: 39585339
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + BMS986205 (IDO-inhibitor)
Study: 39585605
Drug: High-realistic clinical
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-realistic clinical simulation during drug administration
Study: 39585936
Drug: Cilostazol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (50 or 100 mg, twice per day) added to other antiplatelets
Study: 39586309
Drug: Radioiodine group
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone)
Study: 39586616
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) plus azathioprine (AZA) with a 7-day steroid tapering scheme
Study: 39586616
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) with conventional standardised steroid tapering regimen
Study: 39587504
Drug: SSRIs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs with Control treatment
Study: 39587622
Drug: High-concentration platelet-rich
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration platelet-rich plasma (PRP) injection
Study: 39587799
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein breakfast (34 g protein)
Study: 39587796
Drug: Tegoprazan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (50 mg)
Study: 39587825
Drug: Extended DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended DAPT (75 mg clopidogrel plus 75-150 mg aspirin daily)
Study: 39587825
Drug: Monotherapy (75-150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (75-150 mg aspirin daily)
Study: 39587915
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (twice a week for 4 weeks)
Study: 39587931
Drug: PVRV-NG2 (three-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV-NG2 (three-dose regimen)
Study: 39587931
Drug: PVRV-NG2 (two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV-NG2 (two-dose regimen)
Study: 39587931
Drug: HDCV (three-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCV (three-dose regimen)
Study: 39587931
Drug: PVRV (three-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV (three-dose regimen)
Study: 39588131
Drug: Antiresorptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive therapy (ibandronate)
Study: 39588987
Drug: ADS051 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADS051 1,500 mg
Study: 39588987
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose groups of ADS051
Study: 39589133
Drug: BIC 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC 75 mg + LEN 25 mg (n = 51)
Study: 39589133
Drug: BIC 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC 75 mg + LEN 50 mg (n = 52)
Study: 39589133
Drug: BIC 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC 75 mg + LEN 25 mg
Study: 39589133
Drug: BIC 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC 75 mg + LEN 50 mg
Study: 39589133
Drug: BIC +
Normalized name: Bictegravir plus emtricitabine and tenofovir alafenamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC + LEN (both dosing regimens)
Study: 39589314
Drug: Contrast-Enhanced Ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-Enhanced Ultrasound (CEUS) with 2 mL sulfur hexafluoride lipid-type A microspheres (Lumason) per lesion
Study: 39589314
Drug: Hepatobiliary agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatobiliary agent MRI (HBA-MRI)
Study: 39589314
Drug: Hepatobiliary agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatobiliary agent MRI (HBA-MRI) for lesions ≥ 2 cm
Study: 39589664
Drug: Alendronate solution
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate solution (ALN-S)
Study: 39589664
Drug: Alendronate tablet
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate tablet (ALN-T)